GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioceltix SA (WAR:BCX) » Definitions » Common Stock

Bioceltix (WAR:BCX) Common Stock : zł0.49 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bioceltix Common Stock?

Bioceltix's quarterly common stock increased from Mar. 2024 (zł0.41 Mil) to Jun. 2024 (zł0.49 Mil) but then stayed the same from Jun. 2024 (zł0.49 Mil) to Sep. 2024 (zł0.49 Mil).

Bioceltix's annual common stock increased from Dec. 2021 (zł0.33 Mil) to Dec. 2022 (zł0.34 Mil) and increased from Dec. 2022 (zł0.34 Mil) to Dec. 2023 (zł0.41 Mil).


Bioceltix Common Stock Historical Data

The historical data trend for Bioceltix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioceltix Common Stock Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
0.23 0.27 0.33 0.34 0.41

Bioceltix Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.41 0.41 0.49 0.49

Bioceltix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Bioceltix Business Description

Traded in Other Exchanges
N/A
Address
Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.